Search Results - "Vucicevic, D"

Refine Results
  1. 1

    Evaluation of Hypericum perforatum oil extracts for an antiinflammatory and gastroprotective activity in rats by ZDUNIC, G, GODEVAC, D, MILENKOVIC, M, VUCICEVIC, D, SAVIKIN, K, MENKOVIC, N, PETROVIC, S

    Published in Phytotherapy research (01-11-2009)
    “…Oil extracts of Hypericum perforatum L. (Oleum Hyperici) were prepared in three different ways according to the prescriptions from traditional medicine…”
    Get full text
    Journal Article
  2. 2

    Is There a "Weekend Effect" in Multiorgan Transplantation? by Chand, R.R., Lum, C.J., Vaidya, A.S., Pandaya, K., Vucicevic, D., DePasquale, E.C.

    “…Multiple organ transplant surgeries are complicated, prolonged, resource-heavy procedures which may be adversely affected by the timing of the surgery. We used…”
    Get full text
    Journal Article
  3. 3

    Transplant Survival and Competing Outcomes after UNOS Allocation Policy Change by Vucicevic, D., Lum, C., Rahman, J., Chand, R., Vaidya, A., Liu, G., Pandya, K., Salimbangon, A., DePasquale, E.

    “…UNOS allocation took effect in October of 2018 after much long debate. It is unclear what are the implications of this change on transplant outcomes and…”
    Get full text
    Journal Article
  4. 4

    Heart Transplantation Mortality in Recipients with Muscular Dystrophy by Chand, R.R., Vaidya, A.S., Lum, C.J., Vucicevic, D., Pandaya, K., DePasquale, E.C.

    “…We want to compare mortality in heart transplant (HTx) recipients with and without Muscular Dystrophy. Using the United Network of Organ Sharing (UNOS) Organ…”
    Get full text
    Journal Article
  5. 5

    Comparing Mortality in Heart Transplantation Utilizing Donor Hearts with and without CAD by Chand, R.R., Vaidya, A.S., Lum, C.J., Vucicevic, D., Pandaya, K., DePasquale, E.C.

    “…We want to determine if there is a difference in outcomes in heart transplant (HTx) recipients who receive donor hearts with known coronary artery disease…”
    Get full text
    Journal Article
  6. 6

    Heart Retransplantation Outcomes before and after the UNOS Donor Heart Allocation Policy Change by Chand, R., Lum, C.J., Vaidya, A.S., Pandaya, K., Vucicevic, D., DePasquale, E.C.

    “…To compare heart retransplantation (reHTx) mortality six months before and after the United Network of Organ Sharing (UNOS) donor heart allocation policy…”
    Get full text
    Journal Article
  7. 7

    Heart Transplantation Outcomes in Adults with Postpartum Cardiomyopathy by Genyk, P.A., Liu, G.S., Nattiv, J., Banankhah, P., Kingsford, P., Li, J.P., Wolfson, A.M., Vucicevic, D., DePasquale, E.C., Vaidya, A.S.

    “…Postpartum cardiomyopathy (PPCM) is a prevalent cause of end-stage heart failure in women, from which about 10% will require heart transplantation. We aimed to…”
    Get full text
    Journal Article
  8. 8

    Comparison of Six-Month Outcomes in Hypertrophic Cardiomyopathy Patients before and after UNOS Allocation System Change by Li, J.P., Pandya, K., Kingsford, P., Nattiv, J., Liu, G., Vucicevic, D., Genyk, P., Wolfson, A., Banankhah, P., Vaidya, A., DePasquale, E.

    “…HCM patients may have increased waitlist (WL) mortality. Given the recent change in prioritizing patients with restrictive and hypertrophic cardiomyopathy…”
    Get full text
    Journal Article
  9. 9

    Heart Transplant Outcomes in Patients with Alcoholic Cardiomyopathy by Genyk, P., Nuno, S.Barajas, Hashmi, S., Nattiv, J., Banankhah, P., Liu, G., Wolfson, A.M., Vucicevic, D., Vaidya, A.S., DePasquale, E.C.

    “…We sought to better characterize differences in transplant outcomes between patients with alcoholic cardiomyopathy and those with other forms of cardiomyopathy…”
    Get full text
    Journal Article
  10. 10

    Comparison of Six-Month Outcomes in Restrictive Cardiomyopathy Patients before and after UNOS Allocation System Change by Li, J.P., Kingsford, P., Pandya, K., Fong, M., Grazette, L., Nattiv, J., Liu, G., Genyk, P., Vucicevic, D., Chand, R., Kiankhooy, A., Wolfson, A., Vaidya, A., DePasquale, E.

    “…Restrictive cardiomyopathy (RCM) patients represent a spectrum of disorders. Given the greater emphasis for status exceptions for RCM pts in the new allocation…”
    Get full text
    Journal Article
  11. 11

    Heart Transplant Outcomes in Patients Who Receive Hepatitis B Virus (HBV) Positive Donor Hearts by Genyk, P.A., Liu, G.S., Nattiv, J., Banankhah, P., Li, J.P., Kingsford, P.A., Wolfson, A., Vucicevic, D., Vaidya, A.S., DePasquale, E.C.

    “…The advent of anti-viral therapy for HBV has made it possible to expand the donor pool for heart transplant recipients. Little is known in long term outcomes…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14
  15. 15

    Heart Transplantation Outcomes in Patients with Marfan Syndrome: UNOS Registry Analysis by Genyk, P.A., Nattiv, J., Liu, G.S., Banankhah, P., Kingsford, P.A., Li, J.P., Wolfson, A.M., Vucicevic, D., Vaidya, A.S., DePasquale, E.C.

    “…Marfan syndrome (MS) is an autosomal dominant connective tissue disorder that causes a defect in the gene fibrillin-1. MS patients develop advanced…”
    Get full text
    Journal Article
  16. 16

    Outcomes of Heart Transplantation in Adults with Congenital Heart Disease Since UNOS Allocation System Change: UNOS Registry Analysis by Genyk, P.A., Nattiv, J., Liu, G.S., Vucicevic, D., Pandya, K., Chand, R.R., Li, J., Banankhah, P., Kingsford, P.A., Vaidya, A.S., DePasquale, E.C.

    “…Outcomes in cardiac transplantation (HT) in patients with congenital heart disease (CHD) with the UNOS registry are well defined. The UNOS allocation system…”
    Get full text
    Journal Article
  17. 17

    Post-Transplant Outcomes for Patients Based on Their Duration of Smoking Cessation at the Time of Heart Transplant (HT) Listing by Liu, G., Wolfson, A.M., Nattiv, J., Genyk, P., Vucicevic, D., Nuno, S.B., Hashmi, S., Pandya, K., Li, J.P., Kingsford, P.A., Banankah, P., Depasquale, E.C., Ajay, V.S.

    “…Smoking cessation is a prerequisite prior to listing for HT, however the optimal duration of smoking cessation prior to listing is unknown and there is…”
    Get full text
    Journal Article
  18. 18

    Heart Transplant Outcomes for Patients with Cardiac Sarcoidosis by Liu, G.S., Wolfson, A.M., Nattiv, J., Genyk, P.A., Vucicevic, D., Chand, R.R., Pandya, K., Rahman, J., Li, J.P., Kingsford, P., Banankhah, P., DePasquale, E.C., Vaidya, A.S.

    “…Cardiac sarcoidosis (CS) is a known etiology of both end-stage dilated and restrictive cardiomyopathy requiring heart transplantation. We sought to evaluate…”
    Get full text
    Journal Article
  19. 19

    Outcomes of HIV-Positive Patients Post Cardiac Transplantation by Liu, G.S., Wolfson, A.M., Genyk, P.A., Vucicevic, D., Pandya, K., Fong, M., Nattiv, J., Li, J.P., Kingsford, P.A., Banankhah, P., DePasquale, E., Vaidya, A.S.

    “…Contrary to prior practice, human immunodeficiency virus (HIV) positive status is no longer a contraindication to heart transplantation (HT) in many centers…”
    Get full text
    Journal Article
  20. 20